These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 39372203)

  • 1. Advancing cancer therapy: new frontiers in targeting DNA damage response.
    Qian J; Liao G; Chen M; Peng RW; Yan X; Du J; Huang R; Pan M; Lin Y; Gong X; Xu G; Zheng B; Chen C; Yang Z
    Front Pharmacol; 2024; 15():1474337. PubMed ID: 39372203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
    Cheng B; Pan W; Xing Y; Xiao Y; Chen J; Xu Z
    Eur J Med Chem; 2022 Feb; 230():114109. PubMed ID: 35051747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. State-of-the-art strategies for targeting the DNA damage response in cancer.
    Pilié PG; Tang C; Mills GB; Yap TA
    Nat Rev Clin Oncol; 2019 Feb; 16(2):81-104. PubMed ID: 30356138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review.
    Mao X; Lee NK; Saad SE; Fong IL
    Transl Lung Cancer Res; 2024 Feb; 13(2):375-397. PubMed ID: 38496700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of the PARP Inhibitor in
    Inoue T; Sekito S; Kageyama T; Sugino Y; Sasaki T
    Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
    Wang M; Chen S; Ao D
    MedComm (2020); 2021 Dec; 2(4):654-691. PubMed ID: 34977872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA damage response inhibitors: An avenue for TNBC treatment.
    Jin J; Tao Z; Cao J; Li T; Hu X
    Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188521. PubMed ID: 33556453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies.
    Kwok M; Agathanggelou A; Stankovic T
    Blood; 2024 May; 143(21):2123-2144. PubMed ID: 38457665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Directing the use of DDR kinase inhibitors in cancer treatment.
    Brandsma I; Fleuren EDG; Williamson CT; Lord CJ
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1341-1355. PubMed ID: 28984489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATM and ATR as therapeutic targets in cancer.
    Weber AM; Ryan AJ
    Pharmacol Ther; 2015 May; 149():124-38. PubMed ID: 25512053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
    Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
    Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets.
    Khamidullina AI; Abramenko YE; Bruter AV; Tatarskiy VV
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells.
    Takeuchi M; Tanikawa M; Nagasaka K; Oda K; Kawata Y; Oki S; Agapiti C; Sone K; Miyagawa Y; Hiraike H; Wada-Hiraike O; Kuramoto H; Ayabe T; Osuga Y; Fujii T
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31805725
    [No Abstract]   [Full Text] [Related]  

  • 18. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.
    Minchom A; Aversa C; Lopez J
    Ther Adv Med Oncol; 2018; 10():1758835918786658. PubMed ID: 30023007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
    Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
    Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Targeting of DNA Damage Response in Cancer.
    Choi W; Lee ES
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.